Skip to Content Facebook Feature Image

Novonesis Co-Hosts Partnering Day 2025 in Singapore to Advance Biosolutions for a Sustainable Future

Business

Novonesis Co-Hosts Partnering Day 2025 in Singapore to Advance Biosolutions for a Sustainable Future
Business

Business

Novonesis Co-Hosts Partnering Day 2025 in Singapore to Advance Biosolutions for a Sustainable Future

2025-05-14 13:17 Last Updated At:14:05

SINGAPORE, May 13, 2025 /PRNewswire/ -- Novonesis, a world-leading biosolutions company, co-hosted its "Unlocking Value for a Sustainable Future" Partnering Day 2025 in Singapore on May 7 together with Novo Holdings and Flagship Pioneering. The event focused on reshaping the agriculture and food industries through biosolutions and resource recycling. Leaders from food, agri-business, and waste management explored resource optimisation, while industry executives exchanged insights into scaling innovative biosolutions. Investors identified high-growth opportunities in biosolutions and circular economy models for sustainable business impact.

With the global population projected to reach 9.8 billion by 2050, pressure on food systems and sustainability is growing. Biosolutions offer a path forward using microbes, enzymes, and other technologies. The Partnering Day 2025 provided a platform for leaders in business, capital, and innovation to advance circular, bio-based solutions. Showcasing real-world advances including waste valorisation and resource optimisation, the event highlighted how biosolutions are shaping the future of food and agriculture.

The event opened with a welcome address by Rasmus Bjørnø, Deputy Head of Mission at the Royal Danish Embassy in Singapore, followed by a keynote speech from Anders Spohr, Managing Partner and Head of Planetary Health at Novo Holdings, outlining the strategic role of biosolutions in reshaping agriculture and food systems. Representatives from three hosting companies shared their insights on what roles that biosolutions and capital play along the way to foster a more sustainable future. Lensey Chen, APAC President of Novonesis, Ignacio Martinez, General Partner of Flagship Pioneering, together with esteemed speakers from industry, NGOs as well as academia explored topics such as resource efficiency, the bioeconomy, and the importance of partnerships in accelerating the bio-revolution. Case studies highlighted how companies are using biosolutions to unlock new value streams and drive sustainable growth.

With the planet's resources under growing strain, biosolutions are enabling transformation not just in fields and factories, but across entire value chains. In fields, factories, and homes, they are transforming production by unlocking sustainable protein sources and helping farmers increase efficiency while reducing the use of chemicals, fossil resources, energy, and water. Biosolutions also turn waste into high-value products, enabling economic growth in a sustainable way. Copenhagen Economics Report found that if we made more use of just some biosolutions, we could cut global greenhouse gas emissions by up to 4.3 billion tonnes. That's 8% of total global emissions. For every job created in biotech in general, additional 2 jobs are created across the value chain.  

Lensey Chen, APAC President of Novonesis, commented: "We know every customer's needs are unique, our portfolio of biosolutions is the market's broadest, and can be used to expand operations through greater flexibility. This is why partnership is key, I am happy to extend an invitation on behalf of Novonesis as a potential partner, we are here to help take our collaboration to a new level of performance by working together with you."

Deepa Hingorani, Partner and Head of Planetary Health Asia, Novo Holdings added: "The bioeconomy holds exponential potential, and we see partnerships as essential to unlocking it. We hope today marks the beginning of deeper cross-sector collaboration and a shared commitment to shaping a more sustainable future together."

Headquartered in Copenhagen, Novonesis was established in 2024 through the merger of Novozymes and Chr. Hansen—two pioneers in Danish biotechnology. With a portfolio spanning enzymes, microbes, and fermentation-based technologies, the company plays a pivotal role in advancing biosolutions across food, health, agriculture, and sustainability. Partnering Day 2025 reflects Novonesis' ongoing commitment to driving greater impact through innovation, collaboration, and science-based solutions.

About Novonesis 

Novonesis is a global company leading the era of biosolutions. By leveraging the power of microbiology with science, we transform the way the world produces, consumes, and lives. In more than 30 industries, our biosolutions are already creating value for millions of consumers and benefitting the planet. Our 10,000 people worldwide work closely with our partners and customers to transform business with biology.

Learn more at www.novonesis.com

About Novo Holdings

Novo Holdings is a holding and investment company responsible for managing the assets and wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people's health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation. Wholly owned by the Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S (formerly Novozymes A/S) and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure, and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seed, Venture, Growth, Asia, Planetary Health, and Principal Investments teams, Novo Holdings invests in life sciences companies at all stages of development. As of year-end 2024, Novo Holdings had total assets of EUR 142 billion. www.novoholdings.dk

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Novonesis Co-Hosts Partnering Day 2025 in Singapore to Advance Biosolutions for a Sustainable Future

Novonesis Co-Hosts Partnering Day 2025 in Singapore to Advance Biosolutions for a Sustainable Future

Novonesis Co-Hosts Partnering Day 2025 in Singapore to Advance Biosolutions for a Sustainable Future

Novonesis Co-Hosts Partnering Day 2025 in Singapore to Advance Biosolutions for a Sustainable Future

T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors

Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer

Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.

"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."

Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.

 

 

To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.

Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.

"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."

About Alamar Biosciences, Inc. 
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com

 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Recommended Articles